|
1
|
Gavert N and Ben-Ze'ev A:
Epithelial-mesenchymal transition and the invasive potential of
tumors. Trends Mol Med. 14:199–209. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sato M, Shames DS and Hasegawa Y: Emerging
evidence of epithelial-to-mesenchymal transition in lung
carcinogenesis. Respirology. 17:1048–1059. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shirakihara T, Horiguchi K, Miyazawa K,
Ehata S, Shibata T, Morita I, Miyazono K and Saitoh M: TGF-β
regulates isoform switching of FGF receptors and
epithelial-mesenchymal transition. EMBO J. 30:783–795. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kurimoto R, Iwasawa S, Ebata T, Ishiwata
T, Sekine I, Tada Y, Tatsumi K, Koide S, Iwama A and Takiguchi Y:
Drug resistance originating from a TGF-β/FGF-2-driven
epithelial-to-mesenchymal transition and its reversion in human
lung adenocarcinoma cell lines harboring an EGFR mutation. Int J
Oncol. 48:1825–1836. 2016.PubMed/NCBI
|
|
6
|
Lamouille S and Derynck R: Cell size and
invasion in TGF-beta-induced epithelial to mesenchymal transition
is regulated by activation of the mTOR pathway. J Cell Biol.
178:437–451. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li L, Han R, Xiao H, Lin C, Wang Y, Liu H,
Li K, Chen H, Sun F, Yang Z, et al: Metformin sensitizes
EGFR-TKI-resistant human lung cancer cells in vitro and in vivo
through inhibition of IL-6 signaling and EMT reversal. Clin Cancer
Res. 20:2714–2726. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Noble PW, Albera C, Bradford WZ, Costabel
U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA,
Szwarcberg J, et al: Pirfenidone in patients with idiopathic
pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet.
377:1760–1769. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Taniguchi H, Ebina M, Kondoh Y, Ogura T,
Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, et al:
Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J.
35:821–829. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iyer SN, Gurujeyalakshmi G and Giri SN:
Effects of pirfenidone on procollagen gene expression at the
transcriptional level in bleomycin hamster model of lung fibrosis.
J Pharmacol Exp Ther. 289:211–218. 1999.PubMed/NCBI
|
|
11
|
Iyer SN, Gurujeyalakshmi G and Giri SN:
Effects of pirfenidone on transforming growth factor-beta gene
expression at the transcriptional level in bleomycin hamster model
of lung fibrosis. J Pharmacol Exp Ther. 291:367–373.
1999.PubMed/NCBI
|
|
12
|
Gurujeyalakshmi G, Hollinger MA and Giri
SN: Pirfenidone inhibits PDGF isoforms in bleomycin hamster model
of lung fibrosis at the translational level. Am J Physiol.
276:L311–L318. 1999.PubMed/NCBI
|
|
13
|
Di Sario A, Bendia E, Baroni G Svegliati,
Ridolfi F, Casini A, Ceni E, Saccomanno S, Marzioni M, Trozzi L,
Sterpetti P, et al: Effect of pirfenidone on rat hepatic stellate
cell proliferation and collagen production. J Hepatol. 37:584–591.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Garcia L, Hernández I, Sandoval A, Salazar
A, Garcia J, Vera J, Grijalva G, Muriel P, Margolin S and
Armendariz-Borunda J: Pirfenidone effectively reverses experimental
liver fibrosis. J Hepatol. 37:797–805. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Richeldi L, Costabel U, Selman M, Kim DS,
Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G,
et al: Efficacy of a tyrosine kinase inhibitor in idiopathic
pulmonary fibrosis. N Engl J Med. 365:1079–1087. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Richeldi L, du Bois RM, Raghu G, Azuma A,
Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y,
et al: Efficacy and safety of nintedanib in idiopathic pulmonary
fibrosis. N Engl J Med. 370:2071–2082. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wollin L, Maillet I, Quesniaux V, Holweg A
and Ryffel B: Antifibrotic and anti-inflammatory activity of the
tyrosine kinase inhibitor nintedanib in experimental models of lung
fibrosis. J Pharmacol Exp Ther. 349:209–220. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rangarajan S, Kurundkar A, Kurundkar D,
Bernard K, Sanders YY, Ding Q, Antony VB, Zhang J, Zmijewski J and
Thannickal VJ: Novel mechanisms for the Antifibrotic action of
Nintedanib. Am J Respir Cell Mol Biol. 54:51–59. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Turner-Warwick M, Lebowitz M, Burrows B
and Johnson A: Cryptogenic fibrosing alveolitis and lung cancer.
Thorax. 35:496–499. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hubbard R, Venn A, Lewis S and Britton J:
Lung cancer and cryptogenic fibrosing alveolitis. A
population-based cohort study. Am J Respir Crit Care Med. 161:5–8.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Matsushita H, Tanaka S, Saiki Y, Hara M,
Nakata K, Tanimura S and Banba J: Lung cancer associated with usual
interstitial pneumonia. Pathol Int. 45:925–932. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang RY, Kuay KT, Tan TZ, Asad M, Tang
HM, Ng AH, Ye J, Chung VY and Thiery JP: Functional relevance of a
six mesenchymal gene signature in epithelial-mesenchymal transition
(EMT) reversal by the triple angiokinase inhibitor, nintedanib
(BIBF1120). Oncotarget. 6:22098–22113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Conte E, Gili E, Fagone E, Fruciano M,
Iemmolo M and Vancheri C: Effect of pirfenidone on proliferation,
TGF-β-induced myofibroblast differentiation and fibrogenic activity
of primary human lung fibroblasts. Eur J Pharm Sci. 58:13–19. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shin JM, Park JH, Park IH and Lee HM:
Pirfenidone inhibits transforming growth factor β1-induced
extracellular matrix production in nasal polyp-derived fibroblasts.
Am J Rhinol Allergy. 29:408–413. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Choi K, Lee K, Ryu SW, Im M, Kook KH and
Choi C: Pirfenidone inhibits transforming growth factor-β1-induced
fibrogenesis by blocking nuclear translocation of Smads in human
retinal pigment epithelial cell line ARPE-19. Mol Vis.
18:1010–1020. 2012.PubMed/NCBI
|
|
27
|
Wang J, Yang Y, Xu J, Lin X, Wu K and Yu
M: Pirfenidone inhibits migration, differentiation, and
proliferation of human retinal pigment epithelial cells in vitro.
Mol Vis. 19:2626–2635. 2013.PubMed/NCBI
|
|
28
|
Shi Q, Liu X, Bai Y, Cui C, Li J, Li Y, Hu
S and Wei Y: In vitro effects of pirfenidone on cardiac
fibroblasts: Proliferation, myofibroblast differentiation,
migration and cytokine secretion. PLoS One. 6:e281342011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kozono S, Ohuchida K, Eguchi D, Ikenaga N,
Fujiwara K, Cui L, Mizumoto K and Tanaka M: Pirfenidone inhibits
pancreatic cancer desmoplasia by regulating stellate cells. Cancer
Res. 73:2345–2356. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen L, Gibbons DL, Goswami S, Cortez MA,
Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, et al: Metastasis
is regulated via microRNA-200/ZEB1 axis control of tumour cell
PD-L1 expression and intratumoral immunosuppression. Nat Commun.
5:52412014. View Article : Google Scholar : PubMed/NCBI
|
